In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ...
The post hailed “promising results” from a trial of GSK’s PARP inhibitor niraparib in brain cancer patients; the drug, sold as Zejula, is currently approved as a maintenance treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback